neuroendocrine neoplasms

Trials

14,250 participants · First posted Feb 28, 2024

Active, not recruiting

NCT04412629

Cabozantinib in High Grade Neuroendocrine Neoplasms

35 participants · First posted Jun 2, 2020

Completed

NCT03967951

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

70 participants · First posted May 30, 2019

Drugs

View all 14 →

second-generation anti-CALR CAR T-cell therapy (myeloproliferative neoplasms)

Biotech

Approved

Luspatercept(Reblozyl)

Conditions: Anemia

Rx

Small Molecule

Approved

Anagrelide(Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan))

Manufacturer: Alphapharm pty ltd, Roxane laboratories inc +7 more

Conditions: Thrombocythemia

C₁₀H₇Cl₂N₃O · Rx

Organizations

Crinetics

United States

NEOPLAS INNOVATION

United States

News

View all 395 →

last year

Phase 1 Trial Explores Oncolytic Virus SVV-001 with Nivolumab and Ipilimumab in Neuroendocrine Neoplasms

last year

Leads Biolabs Raises $189 Million in Hong Kong IPO, Advances First-in-Class 4-1BB Immunotherapy

last year

Trials

Risk Factors for Neuroendocrine Neoplasms

Cabozantinib in High Grade Neuroendocrine Neoplasms

CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms

Drugs

second-generation anti-CALR CAR T-cell therapy (myeloproliferative neoplasms)

Luspatercept(Reblozyl)

Anagrelide(Xagrid, Agrylin, Anagrelide Viatris (previously Anagrelide Mylan))

Organizations

Crinetics

NEOPLAS INNOVATION

News

Phase 1 Trial Explores Oncolytic Virus SVV-001 with Nivolumab and Ipilimumab in Neuroendocrine Neoplasms

Leads Biolabs Raises $189 Million in Hong Kong IPO, Advances First-in-Class 4-1BB Immunotherapy

uPAR-PET/CT Shows Promise in Primary Breast Cancer Detection, Falls Short in Axillary Staging